Extended (6-Week) Varenicline Preloading: Does it Facilitate Smoking Reduction and Cessation?

PHASE4CompletedINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 28, 2018

Study Completion Date

June 28, 2018

Conditions
Smoking Cessation
Interventions
DRUG

Varenicline

Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment

DRUG

placebo

Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment

Trial Locations (1)

9103102

Shaare Zedek Medical center, Jerusalem

All Listed Sponsors
lead

Shaare Zedek Medical Center

OTHER

NCT02634281 - Extended (6-Week) Varenicline Preloading: Does it Facilitate Smoking Reduction and Cessation? | Biotech Hunter | Biotech Hunter